跳至主要内容
临床试验/NCT02429648
NCT02429648已完成不适用

Timing of DCC in Patients Undergoing Pulmonary Vein Isolation Ablation (PVI) of Persistent/Permanent Atrial Fibrillation

The Cleveland Clinic2 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2009年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
90
试验地点
2
主要终点
Duration of procedure

研究概览

简要总结

The purpose of this study is to compare which strategy is superior in patients with persistent/permanent atrial fibrillation (AF) undergoing ablation, direct current cardioversion (DCC) prior to empirical pulmonary vein isolation (PVI) ; or pulmonary vein isolation (PVI)ablation in atrial fibrillation then Direct current cardioversion (DCC) if the patient remains in atrial fibrillation.

详细描述

Ablation of persistent/permanent Atrial Fibrillation (AF) remains a challenge. There are several strategies to improve the outcomes of persistent/permanent AF ablation. At the Cleveland Clinic one of the commonly used strategies is Direct Current Cardioversion (DCC). Depending on physician preference, patients may be ablated in atrial fibrillation then Direct current cardioverted; or Direct current cardioverted and ablated in sinus rhythm. Neither approach has been shown to be superior. As both approaches are currently being performed based on physician preference, the investigators propose to study and compare both approaches in a randomized fashion for evidence based practice.

The purpose of this study is to compare which standard of care strategy is superior in patients with persistent/permanent Atrial Fibrillation undergoing ablation, direct current cardioversion prior to empirical pulmonary vein isolation; or ablation in atrial fibrillation then direct current cardioversion if the patient remains in atrial fibrillation

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Persistent or long standing persistent AF resistant to anti-arrhythmic medication. Must have been present for more than 2 months
  • Therapeutic anticoagulation for at least three weeks prior to initiation of therapy, or TEE performed prior to the procedure
  • Age >= 18 years old. (Females must be either post-menopausal >12 months, practicing a protocol-acceptable method of birth control
  • Scheduled for Pulmonary Vein Isolation
  • Amiodarone will be stopped at least 3 months prior to procedure

排除标准

  • Reversible causes of AF such as pericarditis, hyperthyroidism
  • Presently with Valvular Heart disease requiring surgical intervention
  • Presently with coronary artery disease requiring surgical intervention
  • Early Post-operative AF (within three months of surgery)
  • Previous MAZE or left atrial instrumentation
  • Life expectancy <= 2 years
  • Social factors that would preclude follow up or make compliance difficult.
  • Contraindication to the use of anti-arrhythmic medications and/or coumadin and heparin
  • Enrollment in another investigational drug or device study
  • Patients with severe pulmonary disease
  • Documented intra-atrial thrombus, tumor, or another abnormality which precludes catheter introduction

结局指标

主要结局

Duration of procedure

时间窗: day of procedure

次要结局

  • Composite of duration of fluoroscopy, and radiation exposure doses(day of procedure)
  • Composite of AT/AF burden and total frequency measured by event monitor, holter and/or EKG(12 months)
  • frequency of symptomatic atrial arrhythmias measured by event monitor, holter, and/or EKG(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Walid Saliba

Walid Saliba, MD

The Cleveland Clinic

研究点 (2)

Loading locations...

相似试验